Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Amundi

Amundi lowered its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 45.3% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,765,686 shares of the company's stock after selling 1,463,440 shares during the period. Amundi owned about 0.15% of Teva Pharmaceutical Industries worth $53,182,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TEVA. Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $1,098,060,000. WCM Investment Management LLC grew its position in Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company's stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its position in Teva Pharmaceutical Industries by 19.2% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company's stock worth $1,402,945,000 after purchasing an additional 7,255,083 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Teva Pharmaceutical Industries by 39,228.4% in the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company's stock valued at $139,296,000 after purchasing an additional 6,878,304 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd increased its stake in shares of Teva Pharmaceutical Industries by 18.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company's stock valued at $1,171,378,000 after purchasing an additional 5,917,423 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the business's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the sale, the executive vice president owned 65,621 shares in the company, valued at $2,237,676.10. The trade was a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Richard Daniell sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the completion of the sale, the executive vice president owned 55,755 shares of the company's stock, valued at approximately $1,973,727. This trade represents a 34.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 300,493 shares of company stock worth $10,537,510 over the last 90 days. 0.54% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $35.05 on Monday. The stock's fifty day simple moving average is $33.24 and its 200 day simple moving average is $32.73. The stock has a market capitalization of $40.30 billion, a price-to-earnings ratio of 58.41, a PEG ratio of 3.70 and a beta of 0.86. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%.The business had revenue of $4.14 billion during the quarter. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TEVA. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an "overweight" rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an "overweight" rating in a research note on Thursday, April 30th. Barclays raised their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an "overweight" rating in a report on Wednesday, May 6th. Bank of America upped their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a "buy" rating in a report on Thursday, April 9th. Finally, Truist Financial raised their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Moderate Buy" and a consensus price target of $42.00.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Analyst upgrade supports the rally. Teva’s shares rose 8.2% following an analyst upgrade, indicating improved confidence in the company’s earnings outlook and branded-drug strategy. Teva Pharmaceutical Industries Stock Price Up 8.2% Following Analyst Upgrade
• Positive Sentiment: Higher outlook and branded-product momentum lifted sentiment. Teva raised the midpoint of its 2026 revenue guidance by $75 million, while targeting AUSTEDO revenue of $2.45 billion-$2.6 billion and AJOVY revenue of $850 million-$870 million. Management said growth across the portfolio is helping offset pressure in its established generic-drug business. Teva Lifts Sales View as Brand-Name Business Gains Traction
• Positive Sentiment: UZEDY delivered record sales. Strong quarterly demand for the long-acting schizophrenia treatment prompted Teva to raise its 2026 UZEDY revenue outlook. Regulatory progress for a once-monthly olanzapine injection and a Tourette syndrome candidate also reinforced the company’s pipeline narrative. Teva Lifts UZEDY Outlook After Record Sales and New FDA Progress
• Neutral Sentiment: Revenue exceeded expectations, but profitability did not. Second-quarter revenue was approximately $4.14 billion and benefited from innovative medicines, but earnings missed estimates. Teva reported a $576 million net loss, largely reflecting Emalex acquisition-related costs and impairment charges, making the quality and sustainability of reported earnings an investor concern. Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
• Negative Sentiment: Heavy put-option activity signals hedging or bearish speculation. Investors acquired 27,659 put options, roughly 168% above typical volume. This does not prove a decline is imminent, but it suggests increased demand for downside protection after the stock’s strong recent run.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.